Cambridge Healthtech Institute’s 4th Annual

Targeting the Microbiome
( 微生物群的标靶化 )



Basic and applied biomedical research from the Human Microbiome Project and other independent studies prove that a disruption of a stable microbiome ecosystem results in dysbioses. This imbalance leads to chronic disease and health conditions. There is great promise in correlating the microbiome compositions with these diseases and using the microbiome as a tool for therapeutic development. Cambridge Healthtech Institute’s 4th Annual Targeting the Microbiome tracks both the scientific and clinical progress being made to discover and develop microbiome-derived biomarkers, drug targets, and bioactive molecules as potential treatments for chronic disease and health conditions. Through interactive sessions and panel discussions, leading researchers and thought leaders will explore how the microbiome can become a potential point of intervention to impact progression to disease.


Who should attend: Directors, Managers, Researchers, and Scientists from pharma, biotechs, academia, government and healthcare organizations working in microbiology, immunology, clinical pathology/pathology, diagnostic alliances, metagenomics, food science & technology, genome sciences & systems biology, computational biology, microbial genomics, molecular biology, therapeutic innovation, biomarkers and personalized medicine, target sciences, diagnostic innovation, infectious disease, and R&D


Coverage will include, but is not limited to:                                        

  • Dynamics of the microbiome on health and disease
  • Techniques and methods of analysis of the microbiome
  • Potential of translational interventions and novel therapeutic targets based on Microbiome R&D
  • Innovation, investment, and collaborations


* 活动内容有可能不事先告知作更动及调整。

Choose your language